Results 61 to 70 of about 32,738 (290)

Intraperitoneal chemotherapy for gastric cancer with peritoneal carcinomatosis: is HIPEC the only answer? [PDF]

, 2014
Gastric cancer with peritoneal carcinomatosis is notorious for its dismal prognosis. While the pathophysiology of peritoneal dissemination is still controversial, the rapid downhill course is universal.
Kwong, DLW, Lam, KO, Law, BTT, Law, SYK
core   +1 more source

Peritoneal carcinosis of ovarian origin [PDF]

, 2010
Epithelial ovarian cancer (EOC) is the second most common genital malignancy in women and is the most lethal gynecological malignancy, with an estimated five-year survival rate of 39%.
Fagotti, A, Fanfani, F, Gallotta, V, Naldini, A, ROMANO, Federico, Rossitto, C, Scambia, G., Vigliotta, M   +7 more
core   +2 more sources

Perioperative anaesthetic management in cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC): a retrospective analysis in a single tertiary care cancer centre

Pleura and Peritoneum, 2022
Cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) is associated with increased morbidity and mortality. We retrospectively analysed the perioperative anesthetic management in patients undergoing HIPEC surgery.
Gupta Raghav, Gupta Nishkarsh, Sirohiya Prashant, Pandit Anuja, Ratre Brajesh Kumar, Vig Saurabh, Bhan Swati, Singh Ram, Kumar Balbir, Bhopale Shweta, Mishra Seema, Garg Rakesh, Bharati Sachidanand Jee, Kumar Vinod, Deo Suryanarayana, Bhatnagar Sushma   +15 more
doaj   +1 more source

Adjuvant hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with colon cancer at high risk of peritoneal carcinomatosis; the COLOPEC randomized multicentre trial [PDF]

, 2015
Background: The peritoneum is the second most common site of recurrence in colorectal cancer. Early detection of peritoneal carcinomatosis (PC) by imaging is difficult.
Aalbers, A.G.J. (Arend), Bemelman, W.A. (Willem), Boerma, D. (Djamila), Bremers, A.J.A. (Andreas), Burger, J.W.A. (Jacobus), Buskens, C.J. (Christianne), Dijkgraaf, M.G.W. (Marcel), Evers, P. (Pauline), Grevenstein, H.M.U. (Helma) van, Hemmer, P.H.J. (Patrick H.J.), Hingh, I.H.J.T. (Ignace) de, Klaver, C.E.L. (Charlotte), Lammers, L.A. (Laureen), Leeuwen, B.L. (B.) van, Meijerink, W.J.H.J. (Jeroen), Musters, G.D. (Gijsbert), Nienhuijs, S.W. (Simon), Pon, J. (Jolien), Punt, C.J.A. (Cornelis), Radema, S.A. (Sandra A.), Ramshorst, B. (Bert) van, Snaebjornsson, P., Tanis, P.J. (Pieter), te Velde, E.A. (Elisabeth A.), Tuynman, J.B., van der Bilt, J.D.W. (Jarmila D.W.), van Ginkel, R.J. (Robert J.), Verwaal, V.J. (Vic J.), Wiezer, M.J. (Marinus), Wilt, J.H.W. (Johannes) de   +29 more
core   +4 more sources

The Delphi and GRADE methodology used in the PSOGI 2018 consensus statement on Pseudomyxoma Peritonei and Peritoneal Mesothelioma

, 2021
Pseudomyxoma Peritonei (PMP) and Peritoneal Mesothelioma (PM) are both rare peritoneal malignancies. Currently, affected patients may be treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy offering long-term survival or even ...
de Hingh, I.,, Deraco, M.,, Glehen, O.,, Govaerts, K.,, Kepenekian, V.,, Kusamura, S.,, Lund University., Lurvink, R.J,, Moran, B.,, PSOGI, Syk, Ingvar,, Van der Speeten, K.,, Villeneuve, L.,   +12 more
core   +1 more source

A Dose-Finding Trial for Hyperthermic Intraperitoneal Cisplatin in Gynecological Cancer Patients Receiving Hyperthermic Intraperitoneal Chemotherapy

Frontiers in Oncology, 2021
Background: To identify the maximum tolerated dose (MTD) of hyperthermic intraperitoneal cisplatin at 43°C among gynecological cancer patients.Methods: In this Phase I dose-finding trial, Bayesian optimal interval (BOIN) design was used.
Chui-ying Chan, Hui Li, Miao-fang Wu, Chang-hao Liu, Huai-wu Lu, Zhong-qiu Lin, Jing Li   +6 more
doaj   +1 more source

Hyperthermic intraperitoneal chemotherapy: Rationale and technique

World Journal of Gastrointestinal Oncology, 2010
The combination of complete cytoreductive surgery and perioperative intraperitoneal chemotherapy provides the only chance for long-term survival for selected patients diagnosed with a variety of peritoneal neoplasms, either primary or secondary to digestive or gynecologic malignancy.
Santiago, González-Moreno, Luis A, González-Bayón, Gloria, Ortega-Pérez   +2 more
openaire   +2 more sources

Aerosolization of nanotherapeutics as a newly emerging treatment regimen for peritoneal carcinomatosis

, 2019
Recent advances in locoregional chemotherapy have opened the door to new approaches for the clinical management of peritoneal carcinomatosis (PC) by facilitating the delivery of anti-neoplastic agents directly to the tumor site, while mitigating adverse ...
Ceelen, Wim, De Smedt, Stefaan, Remaut, Katrien, Shariati, Molood, Willaert, Wouter   +4 more
core   +1 more source

Potential survival benefits from optimized chemotherapy implementation in advanced ovarian cancer: Projections from a microsimulation model.

PLoS ONE, 2019
BackgroundOvarian cancer is often diagnosed in advanced stages, when survival is poor. Treatment advances have been made, but are inconsistently implemented.
Anna P Lietz, Davis T Weaver, Alexander Melamed, Jose Alejandro Rauh-Hain, Jason D Wright, Alexi A Wright, Amy B Knudsen, Pari V Pandharipande   +7 more
doaj   +1 more source

Clinical characteristics, treatment response, and survival outcomes in melanoma patients with cavity carcinomatosis: A retrospective analysis

International Journal of Cancer, EarlyView.
What's New? Cavity carcinomatosis, a late manifestation of cancer, fuels tumor formation throughout a large area, most commonly the peritoneal and pleural cavities. The condition also can lead to resistance to otherwise effective treatment strategies.
Zhongqiao Lin, Li Zhu, Yuyang Huang, Lizhu Chen, Yuping Lu, Yu Chen, Jing Lin   +6 more
wiley   +1 more source